

WHAT IS CLAIMED:

1. A process for treating a human patient having a psychosis which comprises administering to said human a substitute for glycine at the glycine-site or a precursor of said substitute or a glycine precursor, in an amount sufficient to potentiate NMDA receptor-mediated neurotransmission.

2. The process of claim 1 wherein the treatment increases the patient's glycine CNS level.

3. The process of claim 1 wherein, D-serine or D-alanine is administered.

4. The process of claim 1 wherein an amino acid, polypeptide or prodrug which functions as a precursor of glycine synthesis in the CNS is administered.

5. The process of claim 1 wherein an amino acid, polypeptide or prodrug which functions as a precursor of D-serine synthesis in the CNS is administered.

6. The process of claim 1 wherein the psychosis is schizophrenia.

7. The process of claim 1 wherein a substitute for glycine is administered.

8. The process of claim 1 wherein a precursor of a substitute for glycine is administered.

10059362-013102
201810-28265001